Hyperlipidemia Pharmacotherapy Summary

Learning Objectives

  • Define atherosclerotic vascular disease (ASCVD) and its various clinical manifestations.

  • Explain the different cholesterol components (LDL, HDL, triglycerides, total cholesterol) and their specific impact on ASCVD risk.

  • Define appropriate screening criteria for dyslipidemia in different age groups.

  • Identify medications and diseases that can increase specific lipid panel components.

  • Identify key lifestyle modifications, including diet, exercise, and smoking cessation, essential for ASCVD prevention and management.

  • Accurately calculate vascular risk using the validated ACC/AHA Omnibus Risk Estimator.

  • Identify the 4 major statin benefit groups according to the ACC/AHA guidelines.

  • Discuss the details of various cholesterol-lowering pharmacologic therapies, including mechanisms of action, efficacy, and common side effects.

  • Create comprehensive mitigation plans for common statin side effects, such as myalgia and elevated liver enzymes.

  • Develop comprehensive, patient-centered treatment plans for patients at risk for or with established ASCVD.

  • Identify at-risk patients based on their health history, physical examination, and laboratory findings.

ASCVD Overview

Atherosclerotic Cardiovascular Disease (ASCVD) refers to a group of conditions caused by atherosclerosis, a chronic inflammatory disease characterized by the buildup of plaque in the artery walls. This plaque consists of cholesterol, fatty substances, cellular waste products, calcium, and fibrin. The primary forms of ASCVD include:

  • Coronary Heart Disease (CHD):

    • Acute Coronary Syndrome (ACS): Includes unstable angina and myocardial infarction (heart attack).

    • Myocardial Infarction (MI): Death of heart muscle tissue due to prolonged ischemia.

    • Coronary Artery Disease (CAD): Narrowing of the coronary arteries, often leading to angina.

    • Coronary Artery Bypass Graft (CABG): A surgical procedure to improve blood flow to the heart.

  • Cerebrovascular Disease:

    • Transient Ischemic Attack (TIA): A "mini-stroke" with temporary symptoms, serving as a warning sign for future stroke.

    • Ischemic Stroke: Caused by a blockage of blood vessels supplying the brain, leading to brain tissue damage.

  • Aortic Atherosclerotic Disease:

    • Abdominal Aortic Aneurysm (AAA): A localized enlargement of the abdominal aorta, which can rupture.

  • Peripheral Artery Disease (PAD): Narrowing of arteries supplying blood to the limbs, most commonly the legs, causing symptoms like claudication.

ASCVD Risk Factors

Several modifiable and non-modifiable factors significantly increase the risk of developing ASCVD:

  • Hypertension: Persistently elevated blood pressure (e.g., >130/80>130/80 mmHg) damages arterial walls, promoting plaque formation.

  • Diabetes Mellitus: Chronic high blood sugar levels (e.g., HbA1c >6.5 {%}) lead to endothelial dysfunction and accelerated atherosclerosis.

  • Cigarette Smoking: A major modifiable risk factor that directly damages blood vessels, reduces HDL-C, and increases LDL-C oxidation.

  • Family History of Premature CVD: A first-degree male relative with a cardiovascular event before age 55 or a first-degree female relative before age 65.

  • Chronic Kidney Disease (CKD): An estimated glomerular filtration rate (eGFR) <60mL/min/1.73m2<60mL/min/1.73m2 for >3>3 months is associated with increased ASCVD risk.

  • Obesity: A body mass index (BMI) >30kg/m2>30kg/m2 is linked to systemic inflammation, insulin resistance, and dyslipidemia.

  • Dyslipidemia: Abnormal lipid levels, specifically high LDL-C, low HDL-C, and high triglycerides.

  • Age: Risk significantly increases with age, particularly for men >45>45 years and women >55>55 years.

ASCVD Risk Estimation

  • The ACC/AHA Pooled Cohort Equations (PCE) Risk Estimator is used to assess the 10-year risk of a first hard ASCVD event (nonfatal MI, CHD death, or fatal/nonfatal stroke) for individuals aged 40-79 without existing ASCVD. It can also guide therapy decisions for individuals aged 20-39 by estimating lifetime risk.

  • Necessary variables for calculation include: Age, Sex, Race, Total Cholesterol, HDL-C, Systolic Blood Pressure, Diastolic Blood Pressure, current Antihypertensive Treatment status, Diabetes history, and Smoking status.

Cholesterol Ranges

Understanding normal and abnormal cholesterol levels is crucial for risk assessment:

  • Total Cholesterol: Desirable is <200mg/dL<200mg/dL. Values >240mg/dL>240mg/dL are considered high.

  • Triglycerides: Optimal is <150mg/dL<150mg/dL. Borderline high is 150-199 mg/dL; high is 200-499 mg/dL; very high is ≥500mg/dL≥500mg/dL.

  • LDL-C (Low-Density Lipoprotein Cholesterol): Often referred to as "bad" cholesterol. Optimal is <100mg/dL<100mg/dL. Near optimal is 100-129 mg/dL; borderline high is 130-159 mg/dL; high is 160-189 mg/dL; very high is ≥190mg/dL≥190mg/dL.

  • HDL-C (High-Density Lipoprotein Cholesterol): Often referred to as "good" cholesterol. Desirable is >60mg/dL>60mg/dL. For men, >40mg/dL>40mg/dL is considered protective; for women, >50mg/dL>50mg/dL is protective. Levels <40mg/dL<40mg/dL for men and <50mg/dL<50mg/dL for women are considered low and a risk factor.

Dyslipidemia Screening

  • A fasting lipid panel is generally recommended:

    • Once between ages 9-11 and again between 17-21 as part of routine pediatric care to detect familial hypercholesterolemia.

    • Every 4-6 years in adulthood, typically starting at age 20, for individuals without risk factors.

  • More frequent screening (e.g., every 1-2 years) or earlier initiation (e.g., starting at age 20) is warranted for those with ASCVD risk factors (e.g., diabetes, hypertension, family history of premature CVD).

Treatment Guidelines

Statin therapy is recommended for four major benefit groups per ACC/AHA guidelines:

  1. Individuals with Clinical ASCVD: This includes those with a history of ACS, MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or PAD of atherosclerotic origin. High-intensity statin therapy is generally recommended for secondary prevention.

  2. Individuals with Severe Primary Hypercholesterolemia: Defined as an LDL-C level ≥190mg/dL≥190mg/dL. High-intensity statin therapy is recommended to achieve at least a 50% reduction in LDL-C.

  3. Individuals 40-75 years of age with Diabetes Mellitus and an LDL-C of 70-189 mg/dL:

    • Moderate-intensity statin is recommended for all in this group.

    • High-intensity statin is recommended if they have multiple ASCVD risk factors or a 10-year ASCVD risk of \ge 20 {%}.

  4. Individuals 40-75 years of age without ASCVD or Diabetes Mellitus but with an LDL-C of 70-189 mg/dL and an estimated 10-year ASCVD risk of \ge 7.5 {%}.

    • If the 10-year risk is \ge 7.5 {%} but <20 {%} (intermediate risk), moderate-intensity statin therapy is recommended after a clinician-patient risk discussion.

    • If the 10-year risk is \ge 20 {%} (high risk), high-intensity statin therapy is recommended.

    • Consideration of risk-enhancing factors (e.g., family history, CKD, metabolic syndrome, specific inflammatory markers) can guide statin initiation in those with borderline risk (5% to <7.5%).

Pharmacologic Treatments

  • Statins (HMG-CoA Reductase Inhibitors):

    • Mechanism: Inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, primarily in the liver. This leads to increased LDL receptor expression and removal of LDL from the blood.

    • Efficacy: Dose-dependent LDL-C lowering (\approx 20-60 {%} reduction). High-intensity statins (e.g., Atorvastatin 40-80mg, Rosuvastatin 20-40mg) reduce LDL-C by \ge 50 {%}. Moderate-intensity statins (e.g., Atorvastatin 10-20mg, Rosuvastatin 5-10mg, Simvastatin 20-40mg) reduce LDL-C by \approx 30-49 {%}.

    • Side Effects: Common include myalgia (muscle pain). Rare but serious side effects include rhabdomyolysis (severe muscle breakdown), hepatotoxicity (liver damage), and new-onset diabetes mellitus.

    • Monitoring: Baseline liver function tests (LFTs) and lipid panel. Repeat lipid panel 4-12 weeks after initiation or dose change. Creatine kinase (CK) if muscle symptoms develop.

  • Ezetimibe:

    • Mechanism: Selectively inhibits the Niemann-Pick C1-Like 1 (NPC1L1) protein in the small intestine, reducing cholesterol absorption from the diet and bile.

    • Efficacy: Modest LDL-C reduction (\approx 18-22 {%}) when used alone, but provides additional reduction when added to statin therapy.

    • Use: Often used in combination with statins for patients who do not reach their LDL-C goals on statin monotherapy or who are statin-intolerant.

  • PCSK9 Inhibitors (Proprotein Convertase Subtilisin/Kexin type 9 Inhibitors):

    • Mechanism: Monoclonal antibodies (e.g., Alirocumab, Evolocumab) that bind to and inactivate PCSK9, preventing it from degrading LDL receptors on liver cells. This increases the number of LDL receptors available to clear LDL-C from the blood.

    • Efficacy: Substantial LDL-C lowering (\approx 45-60 {%} additional reduction when added to statins).

    • Use: Reserved for very high-risk patients with ASCVD on maximally tolerated statin therapy who require further LDL-C lowering, or for patients with familial hypercholesterolemia.

    • Characteristics: High cost; administered via subcutaneous injection.

  • Bile Acid Sequestrants (BAS):

    • Mechanism: Bind bile acids in the intestinal lumen, preventing their reabsorption. This increases the synthesis of new bile acids from cholesterol, leading to increased LDL receptor expression and reduced LDL-C.

    • Examples: Cholestyramine, Colesevelam, Colestipol.

    • Side Effects: Primarily gastrointestinal (constipation, bloating, dyspepsia). Can also interfere with the absorption of fat-soluble vitamins (A, D, E, K) and other medications.

  • Fibric Acids (Fibrates):

    • Mechanism: Peroxisome proliferator-activated receptor alpha (PPAR-alpha) agonists that primarily decrease hepatic VLDL (very low-density lipoprotein) production and enhance triglyceride clearance.

    • Examples: Gemfibrozil, Fenofibrate.

    • Use: Primarily used for severe hypertriglyceridemia (≥500mg/dL≥500mg/dL) to prevent pancreatitis. Can modestly lower LDL-C and increase HDL-C.

    • Monitoring: Liver enzymes, renal function, and muscle symptoms, especially when combined with statins (increased risk of myopathy).

  • Omega-3 Fatty Acids (Fish Oil):

    • Mechanism: Exact mechanism on triglycerides is complex but involves reducing hepatic triglyceride synthesis and accelerating clearance.

    • Examples: Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) or purified EPA (Icosapent ethyl).

    • Use: High-dose omega-3 fatty acids, particularly icosapent ethyl, are used to further reduce risk in patients with established ASCVD or high-risk diabetes who have elevated triglycerides (≥150mg/dL≥150mg/dL) despite statin therapy.

    • Side Effects: Gastrointestinal upset, potential for increased bleeding risk at high doses.

Monitoring & Goals

  • Regular lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) and safety indicator checks (e.g., LFTs, CK if symptomatic) are essential after treatment initiation or dosage changes (typically 4-12 weeks initially, then annually).

  • Goals:

    • For patients with Clinical ASCVD (secondary prevention) and very high risk: The primary goal is an LDL-C of <55mg/dL<55mg/dL (or \<70 { mg/dL} for high risk) and a non-HDL-C of <80mg/dL<80mg/dL. Step-up therapy (e.g., adding Ezetimibe or PCSK9 inhibitor) is considered if goals are not met.

    • For Primary Hyperlipidemia (without established ASCVD): The primary goal is typically an LDL-C of <100mg/dL<100mg/dL for most high-risk individuals, with a non-HDL-C target often <130mg/dL<130mg/dL. For very high-risk individuals, a goal of <70mg/dL<70mg/dL might be considered.

    • For patients with severe hypertriglyceridemia (e.g., ≥500extmg/dL≥500extmg/dL), the initial goal is to reduce triglycerides to prevent pancreatitis, often with fibrates or high-dose omega-3 fatty acids.